Sublimity Therapeutics

Drug development


HBM contact: Dr Alexander Asam

Company status: private

Sublimity Therapeutics develops the first orally delivered, soluble formulation of Cyclosporin to treat Ulcerative Colitis as topical treatment. The company is in Phase II clinical development as has facilities in Ireland and the USA .

© HBM Partners AG  |  Bundesplatz 1  |  6300 Zug, Switzerland  |  Phone  +41 43 888 7171